天天看點

中國科技期刊卓越行動計劃推介:《癌症生物學與醫學》2024年七期

中國科技期刊卓越行動計劃推介:《癌症生物學與醫學》2024年七期

《癌症生物學與醫學》

Cancer Biology & Medicine

由中國抗癌協會和天津醫科大學惡性良性腫瘤醫院共同主辦,重點關注惡性良性腫瘤轉化研究,緻力于為基礎科研和臨床診療架起溝通的橋梁。期刊現已被SCIE(IF=5.6,5年IF 5.9)、MEDLINE以及PubMed/PubMed Central等國内外主要資料庫收錄。作為OA期刊,讀者可通過此連結浏覽全文http://www.ncbi.nlm.nih.gov/pmc/journals/2000/

中國科技期刊卓越行動計劃推介:《癌症生物學與醫學》2024年七期

Editorial

Unraveling the nexus between cellular senescence and malignant transformation: a paradigm shift in cancer research

Xiaoyu Song, Xiyan Liu, Qiqiang Guo, Hongde Xu and Liu Cao

Epigenetic regulators as the foundation for molecular classification of colorectal cancer

Zhenyu Liu, Xin Zhou and Fuchou Tang

Reviews

中國科技期刊卓越行動計劃推介:《癌症生物學與醫學》2024年七期

Modeling human gastric cancers in immunocompetent mice

Weihong Zhang, Shilong Wang, Hui Zhang, Yan Meng, Shi Jiao, Liwei An and Zhaocai Zhou

中國科技期刊卓越行動計劃推介:《癌症生物學與醫學》2024年七期

Research progress in tumor angiogenesis and drug resistance in breast cancer

Jiancheng Mou, Chenhong Li, Qinghui Zheng, Xuli Meng and Hongchao Tang

中國科技期刊卓越行動計劃推介:《癌症生物學與醫學》2024年七期

Progress on immuno-microenvironment and immune-related therapies in patients with pseudomyxoma peritonei

Qidi Zhao, Tian Wei, Ru Ma, Yubin Fu, Rui Yang, Yandong Su, Yang Yu, Bing Li and Yan Li

Original Article

ACSL3 regulates breast cancer progression via lipid metabolism reprogramming and the YES1/YAP axis

Shirong Tan, Xiangyu Sun, Haoran Dong, Mozhi Wang, Litong Yao, Mengshen Wang, Ling Xu and Yingying Xu

中國科技期刊卓越行動計劃推介:《癌症生物學與醫學》2024年七期

Phase Ib study of anti-EGFR antibody (SCT200) in combination with anti-PD-1 antibody (SCT-I10A) for patients with RAS/BRAF wild-type metastatic colorectal cancer

Ming Bai, Yao Lu, Chunmei Shi, Jianwei Yang, Wei Li, Xianli Yin, Chenghui Huang, Lin Shen, Liangzhi Xie and Yi Ba

繼續閱讀